Akero Therapeutics: A Very Attractive Risk/Reward Opportunity [Seeking Alpha]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
SummaryAK-001 recently released data has high likelihood to correlate with future biopsy data.The company is in the eve of a new stage.Akero Therapeutics may lead in the NASH market in future.In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (NASDAQ:AKROclick hereReleased data confirmed our previous assessment. Now, we would like to draw a more detailed conclusion about Akero Therapeutics, its drug candidate, and possible future prospects. We would like to share our opinion why we are still holding our long positions and why the company's stock price has high upside potential.Akero Therapeutics is focused on metabolic disorders, and the lead drug candidate AKR-001 is being evaluated for the treatment of NASH.AKR-001 is a new hope in NASH treatmentThe company released very promising MRI-PDFF and biomarker results of Phase-2 BALANCED trial (NCT03976401Before looking at the results, let's pay attention to the baseline chara
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHGlobeNewswire
- AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKROPR Newswire
- Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswire
- AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKROBusiness Wire
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)PR Newswire
AKRO
Earnings
- 8/9/24 - Beat
AKRO
Sec Filings
- 9/9/24 - Form SC
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- AKRO's page on the SEC website